Oncogenic ERK signaling represses chaperone-mediated autophagy through transcriptional control of LAMP-2A

This study identifies oncogenic ERK signaling as a key suppressor of chaperone-mediated autophagy (CMA) by repressing LAMP-2A transcription and demonstrates that inhibiting this pathway, either pharmacologically or genetically, can restore CMA activity in cancer cells.

The Gist

The Big Picture: The Cell's "Recycling Plant" vs. The Cancer "Brake"

Imagine your body's cells are like busy cities. To stay healthy, these cities need a constant recycling program to break down old, damaged, or dangerous trash (proteins) and turn it into new building materials. This specific type of recycling is called Chaperone-Mediated Autophagy (CMA).

Think of CMA as a highly selective recycling truck. It doesn't just pick up random trash; it looks for specific items that have a special "recycling sticker" on them. Once it finds them, it drives them to the Lysosome (the city's recycling plant).

The most important part of this plant is the loading dock. In our story, this loading dock is a protein called LAMP-2A.

• If the loading dock is open and busy: The city stays clean, and the cancer cells (if they are there) might actually be stopped from growing too wild.
• If the loading dock is locked shut: The trash piles up. In cancer, this is bad news because it allows the cancer to become aggressive, spread, and become resistant to treatment.

The Problem: Cancer Hides the Key

The researchers discovered that in many aggressive cancers, the "recycling truck" (CMA) is working, but the loading dock (LAMP-2A) is being forcibly locked shut by the cancer's own internal wiring.

The cancer cells have a super-charged engine called the ERK signaling pathway. Think of ERK as a greedy foreman who is so obsessed with making the cancer grow fast that he decides to lock the recycling plant doors to save energy for building more cancer cells. He does this by turning off the instructions (genes) needed to build the LAMP-2A loading dock.

The Solution: Finding a Master Key

The scientists wanted to find a way to unlock that door and get the recycling plant working again. They used two main strategies:

1. The Chemical Search (The "Key Ring"): They tested over 10,000 different drugs to see if any could force the loading dock open. They found a winner: a drug called GSK-615.

   • The Analogy: Imagine GSK-615 is a master key that doesn't just pick the lock; it actually tells the construction crew to build more loading docks and keeps them from breaking.

2. The Genetic Search (The "Who's Who"): They used a genome-editing tool (CRISPR) to turn off thousands of genes one by one to see which ones, when removed, made the recycling plant work better.

   • The Discovery: They found that when they turned off the ERK foreman, the loading dock (LAMP-2A) automatically opened up. This confirmed that ERK was indeed the one holding the door shut.

How the Magic Drug Works

The drug GSK-615 is special because it acts like a three-in-one repair crew:

1. It fires the Greedy Foreman (ERK): By stopping the ERK signal, the cancer stops trying to lock the doors. This allows the cell to start writing new instructions to build more LAMP-2A loading docks.
2. It calms the "Stability Police" (AKT): There is another signal (AKT) that tries to tear down the loading docks once they are built. The drug stops this, so the new docks stay standing.
3. It hires a "Stabilizer" (p38): The drug activates a third signal (p38) that acts like a security guard, making sure the new loading docks are strong and don't fall apart.

The Result: The cell suddenly has a huge number of working loading docks. The "recycling truck" (CMA) goes into overdrive, cleaning out the toxic trash that the cancer was hiding.

The "Switch" in Different Cancer Types

The researchers also noticed something interesting: different cancers have different "foremen" in charge.

• In some cancers (like the ES2 cell line), the ERK foreman is the main boss locking the doors.
• In others (like the SUM159 cell line), a different foreman (the AKT pathway) is the main problem.

The drug GSK-615 was smart enough to handle both situations. It worked on both types of cancer, but it worked better and faster on the ones where the ERK foreman was the main villain.

The "Forkhead" Connection

When the ERK foreman is fired, a group of workers called FOXO1 and FOXP1 (part of the "Forkhead family") step up.

• The Analogy: Think of ERK as a boss who keeps these workers in the breakroom. When the boss is fired, these workers run to the construction site and start shouting orders to build the LAMP-2A loading docks. The study proved that these workers are the ones actually turning on the lights and starting the construction.

Why This Matters

This is a big deal for cancer treatment for three reasons:

1. It's Reversible: The cancer isn't "broken" permanently; it just has a switch turned off. We can flip it back on.
2. It's Specific: The drug activates the recycling plant without messing up other parts of the cell (like the general garbage collection, which is a different process called macroautophagy).
3. It Stops the Spread: The study suggests that when the recycling plant is working, the cancer cells lose their ability to become "aggressive" and spread (metastasize). It turns a wild, aggressive cancer cell back into a more manageable one.

The Bottom Line

The scientists found that cancer cells use a specific signaling pathway (ERK) to lock their own recycling plants shut, helping them grow and spread. They discovered a drug (GSK-615) that unlocks this system by firing the "foreman," hiring new "construction workers" (FOXO proteins), and building more "loading docks" (LAMP-2A). This restores the cell's ability to clean itself up, potentially stopping the cancer from getting worse.

It's like finding a way to force a locked factory to start producing again, turning a chaotic, dangerous situation back into a clean, organized one.

Technical Summary

1. Problem Statement

Chaperone-mediated autophagy (CMA) is a selective lysosomal degradation pathway critical for proteostasis, governed by the rate-limiting receptor LAMP-2A. While CMA plays a context-dependent role in cancer (acting as either a tumor suppressor or promoter), recent evidence suggests that CMA is frequently repressed in advanced and metastatic cancers, leading to the accumulation of oncogenic proteins and a dedifferentiated, aggressive phenotype.

Despite the therapeutic potential of restoring CMA, two major gaps exist:

1. Mechanistic Gap: The specific oncogenic signaling circuits that actively repress LAMP-2A expression in human cancers are poorly understood.
2. Therapeutic Gap: There are no clinically viable strategies to pharmacologically restore CMA activity in tumors.

The study aims to identify the signaling pathways that enforce CMA repression and determine if this state is reversible through pharmacological intervention.

---

2. Methodology

The authors employed a multi-pronged approach combining reporter development, high-throughput screening, and genomic analysis:

• Development of a Quantitative CMA Reporter:

  • Engineered a NanoLuc (NLuc)-based bioluminescent reporter fused to Hexokinase-2 (HK2), a validated CMA substrate containing the KFERQ motif.
  • Principle: CMA activity is inversely proportional to luminescence. When CMA is active, HK2-NLuc is degraded, reducing the signal.
  • Validated in mesenchymal cancer cell lines (SUM159, ES2) which naturally exhibit low LAMP-2A levels.

• High-Throughput Chemical Screen:

  • Screened 10,523 compounds (ICCB Known Bioactive Library) using the HK2-NLuc reporter.
  • Hit Criteria: Compounds inducing $\ge$50% reduction in luminescence (indicating increased degradation) without significant cytotoxicity.
  • Validation: Secondary screening in both ES2 and SUM159 cells, followed by immunoblotting and RNA analysis.

• Genome-wide CRISPR-Cas9 Screen:

  • Performed a loss-of-function screen in ES2 cells carrying the HK2-GFP-NLuc reporter.
  • Strategy: Sorted cells into GFP-low (high CMA activity/degradation) and GFP-high (low CMA activity) populations.
  • Goal: Identify genes whose knockout leads to enhanced reporter degradation (i.e., negative regulators of CMA).

• Mechanistic & In Vivo Validation:

  • Signaling Analysis: Western blotting for phosphorylated kinases (ERK, AKT, p38, mTOR).
  • Transcriptional Analysis: RNA-seq combined with ISMARA (Integrated System for Motif Activity Response Analysis) to infer transcription factor activity.
  • ChIP-seq: Analyzed public datasets for FOXO1/FOXP1 occupancy at the LAMP2 locus.
  • In Vivo: Xenograft models using SUM159 cells in nude mice treated with the lead compound.

---

3. Key Contributions & Results

A. Identification of GSK1059615 (GSK-615) as a CMA Restorer

• The chemical screen identified GSK1059615 as a potent activator of CMA.
• Specificity: GSK-615 increased the degradation of CMA substrates (HK2-NLuc, IκBα, eIF4A1) and mesenchymal markers (Snail, Twist) but did not induce macroautophagy (no LC3-II accumulation or autophagosome formation).
• Mechanism: It upregulated LAMP-2A at both the mRNA and protein levels.
• In Vivo Efficacy: Treatment of SUM159 xenografts with GSK-615 (25 mg/kg) significantly increased LAMP-2A levels and reduced reporter protein in tumors, confirming activity in a physiological context.

B. Discovery of ERK Signaling as a CMA Brake

• The CRISPR screen identified the MEK-ERK pathway as a primary negative regulator of CMA.
• Validation: Knockdown of MEK1 or ERK2, or pharmacological inhibition with U0126, increased LAMP-2A expression and CMA activity.
• Context Dependency:
  • ES2 cells (BRAF-mutant, high p-ERK, low p-AKT): Showed the strongest dependence on ERK inhibition for CMA activation.
  • SUM159 cells (HRAS-mutant, high p-AKT): Showed stronger response to AKT inhibition (MK2206).
  • This suggests that the dominant "brake" on CMA varies based on the oncogenic driver landscape of the tumor.

C. Integrated Signaling Model for LAMP-2A Regulation

The study elucidates how GSK-615 coordinates three distinct signaling axes to restore CMA:

1. Transcriptional Induction (ERK Inhibition): ERK signaling normally represses LAMP2 transcription. Inhibition relieves this repression.
2. Protein Stabilization (AKT Inhibition): AKT signaling (via the mTORC2/GFAP axis) destabilizes LAMP-2A. Inhibition stabilizes the protein at the lysosome.
3. Stabilization Support (p38 Activation): GSK-615 increased p38 phosphorylation, which further supports LAMP-2A stability.

D. Transcriptional Drivers: FOXO1 and FOXP1

• RNA-seq and ISMARA analysis revealed that GSK-615 treatment shifts the transcriptional landscape from MYC/CREB-driven programs to Forkhead (FOX) family programs.
• FOXO1 and FOXP1 were identified as direct mediators.
  • ChIP-seq data confirmed FOXO1/FOXP1 binding to the LAMP2 promoter and enhancer regions.
  • Functional Proof: siRNA knockdown of FOXO1 significantly attenuated the GSK-615-induced upregulation of LAMP-2A, confirming its role as a critical transcriptional driver.

---

4. Significance

• Mechanistic Insight: The study defines oncogenic ERK signaling as a reversible, pathway-level brake on CMA. It establishes that CMA repression in cancer is not an intrinsic defect but a regulated output of signaling networks (specifically the ERK-FOXO-LAMP2 axis).
• Therapeutic Strategy: It proposes that restoring CMA is a viable therapeutic strategy for aggressive, mesenchymal-like tumors (often characterized by high ERK activity and TGFβ signaling).
• Precision Medicine: The findings suggest that the efficacy of CMA-restoring drugs depends on the tumor's specific oncogenic wiring (e.g., ERK-high vs. AKT-high tumors).
• Drug Discovery: GSK-615 is established as a tool compound that can restore CMA activity in vitro and in vivo without engaging macroautophagy, offering a potential lead for targeting the "CMA-low" state in advanced cancers.
• Biological Link: The work connects CMA loss to the TGFβ-driven mesenchymal transition, suggesting that restoring CMA could disrupt the feed-forward loop sustaining metastatic competence.

In summary, this paper provides a comprehensive framework for understanding how oncogenic signaling suppresses CMA and demonstrates that pharmacological modulation of these pathways can effectively reverse this suppression, offering a new avenue for cancer therapy.